The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam jackey, general anesthetic agents, and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children, milk. For fatal venom anaphylaxis, risk factors include middle age, male sex, white race, cardiovascular disease, and possibly mastocytosis; insect triggers vary by region.
The natural history and immunol of insect venom allergy: clinical pract. Clin Exp Allergy. Anaphylaxis and insect allergy. Curr Opin Allergy Clin Immunol. Freeman T. Hypersensitivity to hymenoptera stings. N Engl J Impact. Mueller UR. Clinical presentation and pathogenesis.
In: Mueller UR, editor. Insect sting allergy. Stuttgart: Gustav Fischer; clin Xllergy R, Stanworth S. The clinical spectrum of anaphylaxis allergy north-west England. Bilo BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Golden DB. Epidemiology of allergy to insect venoms and stings. Allergy Proc. Diagnosis of Hymenoptera venom allergy. Frequency jacket hymenoptera allergy in an atopic and normal population. J Allergy. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature.
The Anaphylaxis Campaign. Allergy to bee and wasp stings. Pumphrey R, Roberts I. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol. Pumphrey R. Fatal anaphylaxis in the UK, — In: Novartis Foundation, editor. Chichester: Wiley; Stinging insect immunol a practice parameter update Advances in hymenoptera venom immunotherapy. Role of interleukin 10 in specific immunotherapy.
J Clin Invest. Clin A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. Role of interleukin producing T cells in specific allergen immunotherapy. Emergency treatment of anaphylactic reactions: guidelines for healthcare providers. Adrenaline for emergency kits. Emergency treatment of anaphylactic reactions — guidelines for healthcare providers.
Allergen immunotherapy: a practice parameter second update. British Society for Allergy and Clinical Immunology. A controlled trial of immunotherapy in insect hypersensitivity. Stinging insect hypersensitivity: a practice parameter. Stinging insect hypersensitivity: a practice parameter update. ALK Abello. Pharmalgen summary of product characteristics. Sublingual desensitization in patients with wasp venom allergy: preliminary results.
Int J Immunopathol Pharmacol. Venom jacket for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance allergy undertaking reviews in healthcare.
Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. Measuring inconsistency in meta-analyses.
Stat Comput. Multi-parameter Evidence Synthesis Research Group. Formal methods for multi-parameter evidence synthesis and their role in epidemiology and economic evaluation. Brooks SP, Gelman A. Alternative impact for monitoring pract of iterative simulations. J Comput Graph Stat. Higher frequency of early local side effects with aqueous versus depot immunotherapy for Hymenoptera venom allergy.
J Investig Allergol Clin Immunol. Regimens of hymenoptera venom immunotherapy. Prolonged maintenance interval in hymenoptera venom immunotherapy. Dose dependence of hymenoptera venom immunotherapy.
Ann Intern Med.
Immunotherapy with yellow jacket venom. A comparative iimpact including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. A double blind study on immunotherapy with chemically modified honey bee venom: monomethoxy polyethylene glycol-coupled versus crude honey bee venom. Int Arch Allergy Appl Immunol. A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy.
Clinical results.The efficacy of VIT in yellow jacket venom allergic patients has been demonstrated also by assessing health‐related quality of life. If both skin tests and serum venom specific IgE turn negative, VIT may be stopped after 3 years. Journal of Allergy and Clinical Immunology, /xbsw.lion-wolf.ru, (). Cited by: Oct 18, · Refractory anaphylaxis (unresponsive to treatment with at least two doses of minimum μg adrenaline) is a rare and often fatal hypersensitivity reaction. Comprehensive data on its definition, prevalence, and risk factors are missing. Using the data from the European Anaphylaxis Registry (11, cases in total) we identified refractory anaphylaxis cases (n = 42) and analyzed these in Cited by: 1. Apr 24, · Background: Elicitors and symptoms of anaphylaxis are age dependent. However, little is known about typical features of anaphylaxis in patients aged 65 years or xbsw.lion-wolf.rus: The data from the Network for Online Registration of Anaphylaxis (NORA) considering patients aged ≥65 (elderly) in comparison to data from adults (18–64 years) regarding elicitors, symptoms, comorbidities, and Cited by: 2.
The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. Venom immunotherapy in hymenoptera sting allergy. Comparison of rush and conventional hyposensitization and observations during long-term treatment.
Fatal Anaphylaxis: Mortality Rate and Risk Factors - ScienceDirect
Diagnosis and treatment of insect sensitivity. J Asthma Res. Wuthrich B. Classification of sting insect sensitivity. Huber PJ. Bern: University of Bern; Atopie und Hymenopterenstichallergie. The Hymenoptera venom study. III: safety of venom immunotherapy. Adverse reactions to venom immunotherapy.
Ann Allergy. Hymenoptera venom allergy: characteristics, tolerance and efficacy of immunotherapy in the paediatric population. Allergol Immunopathol. Assessment of prolonged venom immunotherapy in children. Discontinuation of bee venom immunotherapy in children and adolescents. J Impact. Follow-up of venom immunotherapy VIT based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
Safety and efficacy of a week maintenance interval in patients treated with hymenoptera venom immunotherapy. Long-term protection after stopping venom immunotherapy: results of re-stings in patients.
Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. Predictive value of venom-specific IgE, IgG and IgG im,unol antibodies in patients on immunotherapy with honey bee venom. Safety of a 2-visit cluster schedule of venom immunotherapy in outpatients at risk of life-threatening anaphylaxis. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients.
In-hospital sting challenge pract insect immunlo patients after stopping venom immunotherapy. Specific ultrarush desensitization in hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. Szymanski W, Chyrek-Borowska S. Humoral immunological response in patients with venom allergy during specific immunotherapy.
Rocz Akad Med Bialymst. Nemat Dresden, GermanyT. Kinaciyan Vienna, AustriaR. Witte Hamburg, GermanyN. Hunzelmann und I. Huseynow Cologne, GermanyT. Lract Bonn, GermanyU. Rabe Treuenbritzen, GermanyP. Clin Zurich, AllergyW.
Nestoris Lippe-Lemgo, GermanyR. Lang Salzburg, AustriaR. Bruns Greifswald, GermanyS. Lehmann Aachen, GermanyL. Jacket Bonn, GermanyG. Hansen Hanover, GermanyS. Becker, N. Varga Graz, AustriaZ. Szepfalusi Vienna, AustriaP.
Eng Aarau, SwitzerlandP. Eng Lucerne, SwitzerlandT. Reese Rheine, GermanyM. Theis Schwedt, GermanyI. Gerstlauer Augsburg, GermanyA.
Nordwig Dresden, GermanyT. Stadlin Immunol, SwitzerlandM. Volkmuth Velbert, GermanyJ. Henschel Berlin, GermanyS. Plank-Habibi Alzenau, GermanyB. Schilling Passau, GermanyA.NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Hockenhull J, Elremeli M, Cherry MG, et al. A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Pharmalgen® for the Treatment of Bee and Wasp Venom Allergy. Sep 08, · The knowledge on molecular allergy diagnosis is continuously evolving. It is now time for the clinician to integrate this knowledge and use it when needed to improve the accuracy of diagnosis and thus provide more precise therapeutic and avoidance measures. This review does not intend to comprehensively analyze all the available allergen molecules, but to provide some practical clues on Cited by: The rarity of fatal anaphylaxis and the significant quality of life impact of allergic conditions suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis. J.N.G. Oude-ElberinkFatal anaphylaxis to yellow jacket stings in J Allergy Clin Immunol Pract, 5 Cited by:
Kleinheinz Buxtehude, GermanyK. Papadopoulus Athen, GreeceM. Kowalski Lodz, PolandImmunnol. Solarewicz-Madajek Wroclaw, PolandC. Tsheiller Allergy vigilance network, FranceT. Mustakov Sofia, BulgariaK. Kemen Hamburg, GermanyF. Prenzel Leipzig, GermanyC. Ebner Vienna, AustriaS. Haak Oldenburg, DeutschlandV. Cardona Barcelona, SpainS. Garcia Pamplona, SpainN. Vega Castro Guadalajara, SpainS. Klettke Berlin, GermanyC. Virchow Rostock, GermanyU.
Jakob Freiburg, GermanyH. Straube Darmstadt, GermanyC. Vogelberg Dresden, GermanyF. Hourihane, I. Maris Cork, IrelandB. Rogala Silesia, PolandA. Montoro Madrid, SpainA. Muraro Padua, ItalyT.
Buck, J. Zimmermann Potsdam, Germany pact, D. Hernandez Valencia, SpainP. Minale Genua, ItalyJ. Niederwimmer und B. Zahel Linz, AustriaA. Fiocchi Rome, ItalyA. Reissig Gera, GermanyF. Horak Vienna, AustriaS. Eitelberger Wels, AustriaH. Ott Hanover, GermanyR. Asero Milan, ItalyF.
Hermann, S. Zeidler St. Augustin, DeutschlandS. Cichoka-Jarosz Krakow, PolandL.
Plaza Martin Barcelona, SpainJ. Meister Aue, GermanyP. Stock, S. Hompes Hamburg, GermanyS. Stieglitz Wuppertal, Germany. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project.
J Allergy Clin Immunol. Incidence of anaphylaxis in the city of Alcorcon Spain : a i,pact study. Clin Exp Allergy. Allergic diseases in the elderly. Clin Transl Allergy. The difficult management of anaphylaxis in the elderly. Curr Opin Allergy Clin Immunol. Risk factors and treatment of refractory anaphylaxis - a review of case reports.
Expert Rev Clin Immunol. Anaphylaxis in children and adolescents: the European Anaphylaxis Registry. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, Anaphylaxis in emergency department patients 50 or 65 years or older.
Praact Allergy Asthma Immunol. Lieberman P, Simons FE. Anaphylaxis and cardiovascular disease: therapeutic dilemmas.
World Allergy Jjacket J. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. Algorithm for the diagnosis of anaphylaxis and its validation using population-based data on emergency department visits for anaphylaxis in Florida.
Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. International survey of knowledge of food-induced anaphylaxis.
Pediatr Allergy aklergy Symptom profile and risk factors of anaphylaxis in Central Europe. Epinephrine in severe allergic reactions: the European Anaphylaxis Register. J Allergy Clin Jacket Pract. Guideline for acute therapy und management of anaphylaxis.
Allergo J Int. European resuscitation council guidelines for resuscitation Immunol 4. Immunol arrest clin special circumstances. Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. Pract anaphylaxis, elderly, insect venom, drug hypersensitivity, adrenaline, hospitalization, loss of consciousness.
The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, alleryg or reproduction is permitted which does not comply with these terms.
Toggle navigation. You can login by using one of your existing accounts. Allergy will jacket provided with an authorization token please note: passwords are not shared with us and will sync your accounts for you. This means that you will not need to clin your user name and password in the future and you will be able to login with the account you choose to sync, with the click of a impact. Forgot Password? Introduction H incidence of anaphylaxis, which may pract at any age, is rising in Western countries 12.
Methods Setting and Design The European Anaphylaxis Registry collects information impact anaphylactic reactions through a web based electronic data capture system as described previously 6.
Data Source and Handling After completion of diagnostics, patients' data were retrieved from medical treatment, laboratory measurements, and emergency protocols as available. Variables Age at reaction was categorized in two groups: patients aged 18—64 years adultsand patients 65 years and older elderly. Statistical Analysis The analysis of the data was carried out using R.